{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Ubrogepant Reduced Migraine-Related Limitations When Taken During the Prodrome Phase","description":"According to a study published in Neurology, when compared to placebo, this gepant led to significantly greater ability to function normally and a greater reduction in activity limitation when taken during the prodrome phase of an attack. Molly O\u2019Brien has the details in this Migraine Minute News Update.&amp;nbsp;  Read More: https:\/\/bit.ly\/3BY2J9d ","author_name":"Migraine Minute News Update","author_url":"http:\/\/migraineminute.libsyn.com\/","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/34979445\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/256d9f\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/item\/34979445"}